Neurology
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global neurology drug development, clinical trials, regulatory approvals, and market trends. Inform your pharma strategy.
Showing 1–12 of 13 articles
Quick answer
NovaPharmaNews Neurology hub for EMA covers 13 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
GRIN Therapeutics Expands Phase 3 Beeline Study for Radiprodil to Europe for GRIN-NDD Treatment
Stoke Therapeutics Zorevunersen Shows Promise for Dravet Syndrome Treatment Ahead of Q1 2026 Results
Telix Pharmaceuticals' TLX101-Px (Pixlumi) Brain Cancer Imaging Drug Accepted for European Review
Ray Therapeutics RTx-015 Receives EMA PRIME Designation for Retinitis Pigmentosa Treatment
Solid Biosciences Receives European Orphan Drug Designation for SGT-003 Duchenne Muscular Dystrophy Treatment
Reuters Pharma EU: Funding & Dealmaking Key Takeaways
EMA Issues Positive Opinion for Itvisma (Onasemnogene Abeparvovec) Gene Therapy for Spinal Muscular Atrophy
EMA Issues Positive Opinion for Cenrifki (Tolebrutinib) Multiple Sclerosis Treatment
CervoMed's Neflamapimod Shows Brain Volume Increase in Dementia with Lewy Bodies Trial at AAN 2026
Leerink Partners Initiates Medincell Coverage with Outperform Rating Following UZEDY Risperidone LAI FDA Approvals
AskBio's Ametefgene Parvec Enters Phase II Trial for Parkinson's Disease Gene Therapy
AB Science Secures €25 Million Clinical Trial Insurance for Masitinib ALS Phase III Study
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.